Therapeutic ribozyme compositions
CA 2088917 C · Owner: Altman, Sidney · Inventors: Forster, Anthony C.; Altman, Sidney; Guerrier-Takada, Cecilia L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
It is possible to target any RNA molecule for cleavage by RNase P by forming a hybrid region consisting of a short sequence of base pairs followed ay a terminal 3'-NCCA sequence. In the preferred embodiment, the region is formed by addition of an external guide sequence consisting of a nucleotide sequence complementary to the targeted site which includes a 3'-NNCA wherein the sequence hybridizes to the targeted RNA to form a short sequence of double-stranded RNA under conditions promoting cleavage of the substrate at the nucleotide at the 5' side of the basepaired region by the RNase P. Specificity is determined by the complementary sequence. The sequence is preferably ten to fifteen …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 15, 1991 and granted November 12, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 15, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 15, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.